CTRI/2015/10/006244进行中（未招募）未知
A multicenter, open label, balanced, randomized, two treatment, two-period crossover, multi-dose, steady state, bioequivalence study of Nevirapine 400 mg prolonged release tablets,Manufactured by Amneal Pharmaceuticals Pvt. Ltd. India compared to Viramune 400 mg prolonged release tablets, Marketed by Boehringer Ingelheim International GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany in adult HIV1 infected patients under fasting condition. - 15-VIN-479
Amneal Pharmaceuticals Company GmbH0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1. Male or non-pregnant, non-lactating female patients, 18-65 years of age(both inclusive) & BMI 18.5-30 mg/m2, diagnosed with documented HIV-I infection.
- •2. Patient who is already receiving Nevirapine 400 mg per day in combination with at least two antiretroviral drugs (As mentioned in Confidential Protocol Number: 15-VIN-479 Protocol for bioequivalence study of Nevirapine 400 mg prolonged release tablets, Version 01, dated: 10-Jul-2015 Page 7 of 53 inclusion criteria no.3) for at least 14 days prior to first IMP administration and who can be switched to Nevirapine 400 mg prolonged release tablets as per Principal Investigatorâ??s discretion.
- •3. Background HIV therapy with a stable antiretroviral regimen that is recommended in combination with Nevirapine according to British HIV Association clinical guidelines as separately prescribed components and kept constant (in combination and dosage) throughout the whole duration of the study:
- •Zidovudine and lamivudine,
- •Abacavir and lamivudine,
- •Tenofovir and emtricitabine,
- •Tenofovir and lamivudine
- •4. An HIV viral load < 50 copies/mL at screening.
- •5. CD4 counts >50/mm3 at screening.
- •6. History of adequate renal, hepatic and cardiac function.
- •7. Subjects willing and able to adhere to the study assessment schedule and other protocol requirements as evidenced by a written informed consent.
- •8. Sexually active women, unless surgically sterile (at least 6 months prior to study drug administration) or postmenopausal for at least 12-consecutive months, must have a negative serum or urine pregnancy test and must agree to use an effective method of avoiding pregnancy from screening, during study and up to 1 week after the last dose of study drug. Cessation of birth control after this point should be discussed with responsible physician.
- •9. In case of Male patients:Men whose sexual partners are women of childbearing potential must agree to use an effective method to avoid pregnancy of his partner from screening, during study & up to 1-week after last dose of study drug. Cessation of birth control after this point should be discussed with responsible physician.
排除标准
- •1. A history of allergic or adverse reactions to Nevirapine or any comparable or similar product.
- •2. Current treatment with an HIV protease inhibitor.
- •3. Patients with moderate or severe hepatic impairment Child Pugh B or C.
- •4. Screening AST or ALT > 2.5 ULN.
- •5. History of liver function abnormalities upon re-administration of Nevirapine.
- •6. History or presence of cancer.
- •7. Use of concomitant medication (other than the stable background antiretroviral HIV therapy)that may interfere with the pharmacokinetics of Nevirapine within 14 days prior to first dosing.
- •8. Difficulty in swallowing solids like tablets or capsules.
- •9. Patients who are using a prohibited contraceptive method (As per Annexure II).
- •10. Patient had major surgery within 4 weeks prior to study entry, or who have not recovered from prior major surgery.
- •11. Patients with known positivity for HbsAg and HCV.
- •12. An unusual or abnormal diet, for whatever reason e.g. religious fasting.
- •13. Subject participating in any other clinical study or has received treatment with any investigational drug or device within 90 days prior to first dose of investigational medicinal product for the current study.
- •14. Donation of blood (1 unit or 350 ml) within 90 days prior to receiving the first dose of investigational medicinal product for the current study.
- •15. History of difficulty with donating blood or difficulty in accessibility of veins.
- •16. Tested positive for drugs of abuse or breath alcohol test at the screening visit or at the check-in visit.
- •17. Use of any recreational drugs or history of drug addiction.
- •18. Patients with severe hepatic impairment, impaired renal function, impaired cardiac function, any abnormal laboratory tests findings or any other significant concomitant disease condition which in the investigator opinion, might increase the risk to the subject or would be contraindicated or interfere with absorption of the study drug.
- •19. In the opinion of the Investigator, the patient will not be compliant with the requirements of the study procedures.
研究者
相似试验
已完成
不适用
A multicenter, open label, balanced, randomized, two-treatment, two- period, two-sequence, cross-over bioequivalence study of Pegylated Liposomal Doxorubicin HCl injection with that of Doxil® in ovarian cancer patients under fasting condition.CTRI/2014/08/004832Intas Pharmaceuticals Ltd48
已完成
不适用
Bioequivalence study of Risperidone in patients with schizophrenia or bipolar I disorder.CTRI/2018/09/015704Qilu Pharmaceutical Co Ltd24
招募中
不适用
A multicenter, open label,patients with metastatic breast cancer patients under fed (standardized light meal) condition.CTRI/2022/06/043101TTY Biopharm Company Ltd
已完成
不适用
Bioequivalence study of Doxorubicin Hydrochloride Liposome Injection 20 mg/10mL of Dr. Reddyâ??s Laboratories, with that of Doxorubicin Hydrochloride Liposome Injection 20 mg/10mL of Sun Pharmaceutical Ind., in ovarian cancer patientsCTRI/2014/06/004703Dr Reddys Laboratories Limited60
进行中（未招募）
不适用
Study of Paliperidone Palmitate injection 156mg/mL with INVEGA SUSTENNA® Injectable Suspension 156mg/mL in subjects with schizophrenia.CTRI/2020/05/025244Qilu Pharmaceutical Co Ltd